Armata Pharmaceuticals/$ARMP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Armata Pharmaceuticals
Armata Pharmaceuticals Inc is a late clinical-stage biotechnology company focused on the development of high-purity and potent, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary bacteriophage-based technology. It has completed three Phase 2 clinical trials to date. The Company operates and manages its business as one reportable operating segment, which is the business of developing pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat acute and chronic bacterial infections using its proprietary bacteriophage-based technology.
Ticker
$ARMP
Sector
Primary listing
AMEX
Employees
61
Headquarters
Website
ARMP Metrics
BasicAdvanced
$260m
-
-$7.78
-
-
Price and volume
Market cap
$260m
52-week high
$16.34
52-week low
$1.81
Average daily volume
68k
Financial strength
Current ratio
0.644
Quick ratio
0.52
Long term debt to equity
-118.452
Total debt to equity
-119.926
Interest coverage (TTM)
-1.72%
Profitability
EBITDA (TTM)
-30.205
Gross margin (TTM)
-202.13%
Net profit margin (TTM)
-5,432.80%
Operating margin (TTM)
-611.61%
Revenue per employee (TTM)
$90,000
Management effectiveness
Return on assets (TTM)
-25.32%
Return on equity (TTM)
154.70%
Valuation
Price to revenue (TTM)
49.44
Price to book
-0.83
Price to tangible book (TTM)
-0.82
Price to free cash flow (TTM)
-10.51
Free cash flow yield (TTM)
-9.51%
Free cash flow per share (TTM)
-0.674
Growth
Revenue change (TTM)
10.70%
Earnings per share change (TTM)
613.42%
3-year revenue growth (CAGR)
0.87%
3-year earnings per share growth (CAGR)
87.21%
What the Analysts think about ARMP
Analyst ratings (Buy, Hold, Sell) for Armata Pharmaceuticals stock.
ARMP Financial Performance
Revenues and expenses
ARMP Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs